NeuroSense Therapeutics (NRSNW) Expected to Announce Quarterly Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSNW) is expected to be releasing its results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($0.1950) per share and revenue of $0.2680 million for the quarter.

NeuroSense Therapeutics Stock Performance

Shares of NASDAQ:NRSNW opened at $0.07 on Monday. The business has a fifty day moving average of $0.10 and a two-hundred day moving average of $0.14. NeuroSense Therapeutics has a 52-week low of $0.04 and a 52-week high of $0.70.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.